Bioblast Pharma

Hope should not be rare

Ran Nussbaum

Ran Nussbaum

Ran Nussbaum

Bioblast Pharma Board of Directors Member

Ran Nussbaum has been a director at Bioblast since July 1, 2013. Mr. Nussbaum is a managing partner and the co-founder of The Pontifax Group, which established 3 funds with over $220 million under management and over 30 portfolio companies. Over the past 10 years’, Mr. Nussbaum has been managing The Pontifax Group’s activity together with Tomer Kariv. From 2006 to 2008 he also served as CEO of Biomedix Ltd. and Spearhead Ltd., and was Chairman of the Board of Nasvax Ltd. Mr. Nussbaum’s experience in the life sciences arena coupled with 10 years’ experience in the business intelligence field create a unique blend of skills, enabling him to support companies from inception to commercialization. Mr. Nussbaum also serves on the Boards of Directors of many of The Pontifax Group’s portfolio companies, including Kite Pharma Inc., c-CAM Biotherapeutics Ltd., Insuline Ltd. (public co.), Eloxx, TheraCoat, CollPlant (public), ProTab, Quiet, and Fusimab Ltd, and as Ocon Chairman of the Board.

Learn about other members of the Board of Directors of Bioblast